Noble Capital Markets Reiterates Buy Rating for Unicycive Therapeutics
Noble Capital Markets maintains its buy rating on Unicycive Therapeutics with a $50 price target, a 937.62% upside from the current price.
Key Points
- Noble Capital Markets reiterated its buy rating on Unicycive Therapeutics, Inc. with a price target of $50 on July 1, 2026.
- Noble Capital Markets's $50 price target implies 937.62% upside from Unicycive Therapeutics, Inc.'s ($UNCY) current $4.82 share price.
- Shares of NasdaqCM:UNCY traded near $4.59 on Wednesday, with a market cap of about $128.5 million and a beta of 1.726.
- Vanguard Capital Management LLC opened a new position in Unicycive, while Millennium Management LLC increased its stake by 384,505 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Noble Capital Markets reiterated its buy rating on Unicycive Therapeutics, Inc. (NasdaqCM:UNCY) on July 1, 2026, maintaining a price target of $50. This move by analyst Robert LeBoyer signals continued confidence in the biotechnology company.
Other Institutional Activity in Unicycive Therapeutics
Vanguard Capital Management LLC opened a new position in Unicycive, acquiring 811,430 shares valued at approximately $5.34 million. Millennium Management LLC increased its holdings by 384,505 shares, bringing its total to 1,399,348 shares worth about $9.21 million. Meanwhile, Vivo Capital, LLC, Octagon Capital Advisors LP, Nantahala Capital Management, LLC, and Great Point Partners LLC maintained their existing positions without any change in share count.
Unicycive Therapeutics, Inc. Stock Down 8.5%
Shares of NasdaqCM:UNCY traded near $4.59 on Wednesday. Unicycive Therapeutics has a market cap of approximately $128.5 million and a forward P/E ratio of 0.86. The stock's beta is 1.726, indicating higher volatility compared to the market. It has a 52-week low of $3.71 and a high of $8.74, with a 50-day moving average of $7.56 and a 200-day moving average of $6.25. The company maintains a current ratio of 2.399 and a quick ratio of 2.061, with a debt-to-equity ratio of 2.162.
$UNCY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Unicycive Therapeutics, Inc.
On May 14, 2026, several insiders at Unicycive Therapeutics purchased shares. CEO Shalabh Gupta acquired 762,200 shares, while EVP Pharmaceuticals and BD Pramod Gupta, EVP Corporate Strategy Douglas Jermasek, and CFO John Townsend each bought 169,500 shares. Additionally, Sara Kenkare-Mitra and Sandeep Laumas purchased 126,300 shares each. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On July 1, 2026, Noble Capital Markets maintained its buy rating for Unicycive Therapeutics with a $50 price target. Other firms, including HC Wainwright & Co. and B. Riley Securities, also maintained their buy ratings with targets of $15 and $22, respectively. The consensus among analysts is a strong buy, with a mean target price of $41.3 based on 10 opinions.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc. is a biotechnology company focused on developing therapies for kidney diseases. Headquartered in Mountain View, California, the company is led by CEO Dr. Pramod Gupta. It is working on treatments like oxylanthanum carbonate for hyperphosphatemia and UNI-494 for acute kidney injury, among other projects.
Bottom Line
Noble Capital Markets' reiterated buy rating for Unicycive Therapeutics underscores the firm's optimism about the company's prospects. Investors will be watching how the company's clinical developments unfold. This analyst update reflects opinions as of early July 2026 and may not indicate future performance.
Get Unicycive Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $UNCY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.